Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Urologic Neoplasms × atezolizumab × Clear all

Phase

Phase 1 2 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 51 Carcinoma, Hepatocellular 27 Breast Neoplasms 24 Small Cell Lung Carcinoma 18 Triple Negative Breast Neoplasms 17 Lung Neoplasms 16 Urinary Bladder Neoplasms 14 Neoplasms 14 Neoplasm Metastasis 14 Melanoma 14 Carcinoma, Transitional Cell 14 Colorectal Neoplasms 13 Uterine Cervical Neoplasms 9 Head and Neck Neoplasms 7 Carcinoma, Renal Cell 7 Stomach Neoplasms 6 Recurrence 6 Prostatic Neoplasms 6 Squamous Cell Carcinoma of Head and Neck 5 Sarcoma 5 Mesothelioma, Malignant 5 Liver Neoplasms 5 Carcinoma, Squamous Cell 5 Ovarian Neoplasms 4 Carcinoma, Merkel Cell 4 Thoracic Neoplasms 3 Solid Tumors 3 Rectal Neoplasms 3 Lymphoma, Follicular 3 Lymphoma 3

Interventions

Gemcitabine 5 Trastuzumab 3 pembrolizumab 2 Pemetrexed 2 Paclitaxel 2 Carboplatin 2 vinflunine 1 niraparib 1 montanide ISA 51 1 flt3 ligand protein 1 enfortumab vedotin 1 cabozantinib 1 atezolizumab 1 abemaciclib 1 Zoledronic Acid 1 Urinary Diversion 1 Therapeutics 1 Thalidomide 1 Sunitinib 1 Radiosurgery 1 MART-1 Antigen 1 Immunoglobulins, Intravenous 1 Immune Checkpoint Inhibitors 1 Drug Therapy 1 Dosage Forms 1 Cystectomy 1 Cisplatin 1 Cetuximab 1 CP protocol 1 Biological Therapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05038657 2022-10-03

AURORA

University Hospital Southampton NHS Foundation Trust

Phase 2 Unknown

Carcinoma, Squamous Cell, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡